Kodiak Sciences to present topline DAYBREAK results Sept. 28, 2026

Kodiak Sciences said it will present topline results on Sept. 28, 2026 from the DAYBREAK pivotal Phase 3 study of Zenkuda and KSI-501 in patients with wet age-related macular degeneration.